Promising clinical results for novel antiviral onradivir for flu

 A phase 3 trial of the drug, focusing on the 600-mg dose, is under way.

Related Keywords

Zhongsheng ,Anhui ,China ,Chinese ,Lynda Coughlan ,Bowonpat Sakaew ,Kathleen Neuzil ,University Of Maryland School Medicine Center ,Global Health ,Vaccine Development ,Lancet Infectious ,Zhongsheng Pharmaceutical ,Maryland School ,Medicine Center ,